Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (IOVA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · IOVA · as of Sep 30, 2025
Ownership Breakdown
263
Institutional Holders
▲ 6 vs Q2
$462.29M
Total Inst. Value
▲ $82.99M vs Q2
357.53M
Shares Outstanding
freeFloat 83.86%
213.04M
13F Shares Held
▼ 7.25M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
IOVA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
MHR FUND MANAGEMENT LLC biological products, (no diagnostic substances) | 28.97M | 8.66% | 8.66% | $62.86B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 25.96M | 7.76% | 7.76% | $56.33B | Nov 12, 2025 | ▲ 2.72M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 24.06M | 7.19% | 7.19% | $52.21B | Nov 7, 2025 | ▼ 1.02M |
STATE STREET CORP biological products, (no diagnostic substances) | 13.31M | 3.98% | 3.98% | $28.88B | Nov 14, 2025 | ▲ 3.42M |
INVENOMIC CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 10.54M | 3.15% | 3.15% | $22.88B | Nov 14, 2025 | ▲ 2.25M |
LONG FOCUS CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 9.12M | 2.73% | 2.73% | $19.78B | Nov 14, 2025 | ▼ 2.70M |
PALO ALTO INVESTORS LP biological products, (no diagnostic substances) | 7.62M | 2.28% | 2.28% | $16.53B | Nov 14, 2025 | ▲ 4.19M |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 6.87M | 2.05% | 2.05% | $14.91B | Nov 12, 2025 | ▲ 679.2K |
GOLDMAN SACHS GROUP INC biological products, (no diagnostic substances) | 6.58M | 1.97% | 1.97% | $14.27B | Nov 14, 2025 | ▲ 1.83M |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 6.28M | 1.88% | 1.88% | $13.63B | Feb 3, 2026 | ▲ 2.25M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
24
Increased
+23.23M shares1
New Positions
first time holders19
Decreased
−21.19M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.04M
+23.23M / −21.19M
Net new holders
+6
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
IOVA insider trading · insider activity
Source: SEC Form 4
1
Buy transactions
2
Sell transactions
0.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Vogt Frederick G Interim CEO & General Counsel | Jun 1, 2026 | Tax Withhold | 17,701 | $3.96 | $70.1K | 553.5K | Form 4 ↗ |
Puri Raj K. Chief Regulatory Officer | Jun 1, 2026 | Tax Withhold | 2,508 | $3.96 | $9.9K | 242.2K | Form 4 ↗ |
GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Jun 1, 2026 | Tax Withhold | 4,473 | $3.96 | $17.7K | 136.3K | Form 4 ↗ |
BILINSKY IGOR Chief Operating Officer | Jun 1, 2026 | Tax Withhold | 4,473 | $3.96 | $17.7K | 130.1K | Form 4 ↗ |
Kirby Daniel Gordon Chief Commercial Officer | May 11, 2026 | Tax Withhold | 2,435 | $3.70 | $9.0K | 146.9K | Form 4 ↗ |
Roche Corleen M. Chief Financial Officer | Mar 9, 2026 | Award | 132,200 | — | — | 132.2K | Form 4 ↗ |
Vogt Frederick G Interim CEO & General Counsel | Mar 9, 2026 | Award | 235,000 | — | — | 235.0K | Form 4 ↗ |
Puri Raj K. Chief Regulatory Officer | Mar 9, 2026 | Award | 117,500 | — | — | 117.5K | Form 4 ↗ |
GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Mar 9, 2026 | Award | 58,750 | — | — | 58.8K | Form 4 ↗ |
Kirby Daniel Gordon Chief Commercial Officer | Mar 9, 2026 | Award | 132,200 | — | — | 132.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Iovance Biotherapeutics, Inc. (IOVA) is primarily owned by institutional investors, who hold approximately 59.6% of total shares outstanding. Company insiders own approximately 16.14%, while retail and public investors account for the remaining 24.28%.
The largest institutional shareholder of Iovance Biotherapeutics, Inc. is MHR FUND MANAGEMENT LLC, holding approximately 28.97 million shares — equal to 8.66% of outstanding shares — as of September 30, 2025.
A total of 263 institutional investors currently hold IOVA stock, with a combined institutional value of approximately $462,294,782 as of the most recent 13F filing period.
Frequently asked questions
IOVA ownershipIovance Biotherapeutics, Inc. (IOVA) is primarily owned by institutional investors, who hold approximately 59.6% of shares. The largest shareholder is MHR FUND MANAGEMENT LLC with a 8.66% stake. Company insiders hold 16.14%. Data sourced from SEC Form 13F as of September 30, 2025.